Gilead Becomes Third To Market In Second-Line PBC, With Label Advantages

Gilead will make the case that Livdelzi is a better treatment option than Ocaliva or recently approved Iqirvo due to its ability to alleviate pruritus and reduce ALP levels.

FDA approved
Gilead is third to market in second-line PBC therapy with Livdelzi

Gilead Sciences, Inc. made a substantial bet on moving into a different kind of liver disease with its $4.3bn takeout in February of CymaBay Therapeutics, Inc., and that transaction is beginning to bear fruit with the US Food and Drug Administration approval on 14 August of Livdelzi (seladelpar) for second-line treatment of primary biliary cholangitis (PBC). In that setting, Livdelzi will compete against two second-line agents, Alfasigma S.p.A.’s Ocaliva (obeticholic acid), approved in 2016, and Ipsen SA/Genfit SA’s Iqirvo (elafibranor), which obtained FDA approval in June.

In an interview with Scrip, Gilead executive director of global medical affairs for liver diseases Carrie Frenette declined to offer...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from New Products

More from Scrip

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By 

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, which houses flagship publications Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Wave of Biopharma Licensing Deals in India: ‘The Model Is Working’

 

From vonoprazan and inclisiran to nirsevimab, big pharma has licensed several products to Indian firms as have other biopharma players. Experts discuss the intricacies of such licensing deals amid signs of more action in store and whether geopolitics could dull partnering with Chinese firms.